IMNM FY 2024 Earnings — Immunome, Inc. Revenue & Financial Results | Market Cap Arena

IMNMImmunome, Inc.

$2B

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$9M-35.5% YoY

Gross Profit

$9M100.0% margin

Operating Income

-$306M-3382.4% margin

Net Income

-$293M-3240.4% margin

EPS (Diluted)

$-5.00

Cash Flow

Operating Cash Flow

-$111M

Free Cash Flow

-$164M

Stock-Based Comp.

$16M

Balance Sheet

Total Assets

$240M

Total Liabilities

$59M

Stockholders' Equity

$181M

Cash & Equivalents

$143M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9M	$14M	-35.5%
Gross Profit	$9M	$14M	-35.5%
Operating Income	-$306M	-$110M	-179.2%
Net Income	-$293M	-$107M	-174.3%